Immunovant positions IMVT-1402 as lead MG treatment candidate
IImmunovant is prioritizing IMVT-1402 as its lead MG treatment candidate, with registrational clinical trials possible in the next year.| Myasthenia Gravis News
IImmunovant is prioritizing IMVT-1402 as its lead MG treatment candidate, with registrational clinical trials possible in the next year.| Myasthenia Gravis News
